These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29082598)

  • 1. Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?
    Packer M
    Eur J Heart Fail; 2018 Apr; 20(4):627-629. PubMed ID: 29082598
    [No Abstract]   [Full Text] [Related]  

  • 2. Inotropic drugs in the treatment of heart failure.
    Scholz H
    Hosp Pract (Off Ed); 1984 May; 19(5):57-67, 70-1. PubMed ID: 6143760
    [No Abstract]   [Full Text] [Related]  

  • 3. Inotropic infusions for chronic congestive heart failure: medical miracles or misguided medicinals?
    Ewy GA
    J Am Coll Cardiol; 1999 Feb; 33(2):572-5. PubMed ID: 9973041
    [No Abstract]   [Full Text] [Related]  

  • 4. Does glucagon have a positive inotropic effect in the human heart?
    Hernández-Cascales J
    Cardiovasc Diabetol; 2018 Nov; 17(1):148. PubMed ID: 30482191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1.
    Colucci WS; Wright RF; Braunwald E
    N Engl J Med; 1986 Jan; 314(5):290-9. PubMed ID: 2867470
    [No Abstract]   [Full Text] [Related]  

  • 6. Dipeptidyl Peptidase 4 Inhibition Alleviates Shortage of Circulating Glucagon-Like Peptide-1 in Heart Failure and Mitigates Myocardial Remodeling and Apoptosis via the Exchange Protein Directly Activated by Cyclic AMP 1/Ras-Related Protein 1 Axis.
    Aoyama M; Kawase H; Bando YK; Monji A; Murohara T
    Circ Heart Fail; 2016 Jan; 9(1):e002081. PubMed ID: 26721911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure.
    Morgan JP; Erny RE; Allen PD; Grossman W; Gwathmey JK
    Circulation; 1990 Feb; 81(2 Suppl):III21-32. PubMed ID: 2153479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure.
    Katz AM
    Circulation; 1986 Mar; 73(3 Pt 2):III184-90. PubMed ID: 2417747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive inotropic agents in congestive heart failure.
    Homoud MK; Chuttani K; Konstam MA
    Coron Artery Dis; 1993 Jan; 4(1):44-52. PubMed ID: 7903591
    [No Abstract]   [Full Text] [Related]  

  • 10. When is cAMP not cAMP? Effects of compartmentalization.
    Bers DM; Ziolo MT
    Circ Res; 2001 Aug; 89(5):373-5. PubMed ID: 11532895
    [No Abstract]   [Full Text] [Related]  

  • 11. Appearance of a ventricular 5-HT4 receptor-mediated inotropic response to serotonin in heart failure.
    Qvigstad E; Brattelid T; Sjaastad I; Andressen KW; Krobert KA; Birkeland JA; Sejersted OM; Kaumann AJ; Skomedal T; Osnes JB; Levy FO
    Cardiovasc Res; 2005 Mar; 65(4):869-78. PubMed ID: 15721867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inotropic drugs for treatment of the failing heart.
    Maskin CS; Le Jemtel TH; Sonnenblick EH
    Cardiovasc Clin; 1984; 14(3):1-17. PubMed ID: 6327040
    [No Abstract]   [Full Text] [Related]  

  • 13. Inotropic drugs for the treatment of heart failure.
    Mancini DM; Keren G; Aogaichi K; LeJemtel TH; Sonnenblick EH
    J Clin Pharmacol; 1985 Oct; 25(7):540-54. PubMed ID: 2866200
    [No Abstract]   [Full Text] [Related]  

  • 14. [Positive inotropic substances--therapeutic perspectives].
    Erdmann E; Böhm M
    Z Kardiol; 1991; 80 Suppl 8():57-62. PubMed ID: 1796636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New positive inotropic agents.
    Jafri SM; Bristol JA
    Henry Ford Hosp Med J; 1986; 34(3):188-92. PubMed ID: 3542907
    [No Abstract]   [Full Text] [Related]  

  • 16. Enhanced relaxation and reduced positive inotropic effects of amrinone in ventricular muscle from cats with subacute heart failure. Implications for drug therapy.
    Bassett AL; Gaide MS; Lodge NJ; Cameron JS
    Adv Myocardiol; 1985; 6():629-36. PubMed ID: 2986264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward biologically targeted therapy of calcium cycling defects in heart failure.
    Ikeda Y; Hoshijima M; Chien KR
    Physiology (Bethesda); 2008 Feb; 23():6-16. PubMed ID: 18268360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New pharmacologic interventions to increase cardiac contractility: challenges and opportunities.
    Movsesian M
    Curr Opin Cardiol; 2015 May; 30(3):285-91. PubMed ID: 25807221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application of non-glycoside inotropic agents in newborn infants].
    Umans-Eckenhausen MA; Terlouw JF; Szatmari A; van den Anker JN
    Tijdschr Kindergeneeskd; 1993 Feb; 61(1):13-20. PubMed ID: 8493697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inotropes.
    Francis GS; Bartos JA; Adatya S
    J Am Coll Cardiol; 2014 May; 63(20):2069-2078. PubMed ID: 24530672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.